Naveen Pemmaraju, Director of Leukemia-Cancer Network, Executive Director of Cancer Medicine, Director of BPDCN at the Department of Leukemia, and Professor at the Department of Leukemia at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues, published in Leukemia and Lymphoma:
“An important, clinically relevant paper and focus on practical management approaches for our BPDCN field led by Andy Lane and Naveen Pemmaraju on CLS prevention and treatment with CD123 therapy in BPDCN.”
Title: Optimizing capillary leak syndrome prevention and management in patients receiving tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
Authors: Andrew A. Lane, Cristina Papayannidis, Emanuele Angelucci, James McCloskey, Gary J. Schiller, Adolfo de la Fuente Burguera, Pau Montesinos, Yasir Nagarwala, Marco Herling, Gabriel Mannis, Naveen Pemmaraju
You can read the Full Article in Leukemia and Lymphoma.
More posts featuring Naveen Pemmaraju.